Alethia Young
Known title: DirectorCIK: 0001918147
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
Transaction History
| PCRX | ▲ Buy | Grant | 6,405 | $0 | 6/10/2026 | View on chart |
| BCYC | ▼ Sell | Open Market | 2,456 | $16K | 1/5/2026 | View on chart |
| BCYC | ▼ Sell | Open Market | 1,878 | $12K | 1/5/2026 | View on chart |
| BCYC | ▼ Sell | Open Market | 3,289 | $22K | 1/2/2026 | View on chart |
| BCYC | ▲ Buy | Grant | 50,000 | $0 | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/2/2026 | View on chart |
| BCYC | ▼ Sell | Open Market | 217 | $2K | 10/2/2025 | View on chart |
| BCYC | ▼ Sell | Open Market | 265 | $2K | 10/2/2025 | View on chart |
| BCYC | ▼ Sell | Open Market | 204 | $1K | 7/2/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 6,163 | $0 | 6/11/2025 | View on chart |
| BCYC | ▼ Sell | Open Market | 215 | $2K | 4/2/2025 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/3/2025 | View on chart |
| BCYC | ▼ Sell | Open Market | 1,395 | $20K | 1/2/2025 | View on chart |
| BCYC | ▲ Buy | Grant | 35,000 | $0 | 1/2/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 2/15/2024 | View on chart |
| BCYC | ▲ Buy | Grant | 12,000 | $0 | 1/2/2024 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 7,000 | $195K | 9/6/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 7,000 | $279K | 9/6/2023 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 4,666 | $130K | 9/6/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 4,666 | $186K | 9/6/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/5/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 1,867 | $0 | 6/9/2022 | View on chart |
| PTCT | ▲ Buy | Grant | 3,200 | $0 | 6/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.